<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94278">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01877564</url>
  </required_header>
  <id_info>
    <org_study_id>138647</org_study_id>
    <nct_id>NCT01877564</nct_id>
  </id_info>
  <brief_title>A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women</brief_title>
  <official_title>A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine the effects of Metformin, a well tolerated drug
      widely prescribed for treatment of Type 2 Diabetes Mellitus, on endometrium cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IHC-based tissue markers of proliferation: ki67, phosphorylated histone H3, estrogen receptor (ER), progesterone receptor (PR), and telomerase (hTERT)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Adenocarcinoma of the Endometrium</condition>
  <arm_group>
    <arm_group_label>Group 1 - Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral metformin at 500 mg twice a day for 14-21 days followed by surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Group 1 - Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmed diagnosis of grade I or II adenocarcinoma of the endometrium

          -  Must be obese as defined by a body mass index (BMI) greater than or equal to 30 kg/m2

          -  Candidate for surgical removal of their uterus as part of their endometrial cancer
             treatment

          -  Subjects must have signed informed consent

          -  Age 42 - 65 years of age

          -  Electrocorticogram (ECOG) Performance status of 0 - 2

          -  History of adequate renal, liver, and bone marrow function:

               -  Hb: (adequate for surgical intervention, with transfusion if necessary) White
                  Blood Cell (WBC): (normal range)

               -  Platelets: (180K/cmm)

               -  Liver Function Test(LFTs): Normal bilirubin (&lt;2.0mg/dL), AST/ALT (2xULN)

               -  Renal function: creatinine less than 1.4

          -  Female subjects must either not be of child-bearing potential or must have a negative
             urine pregnancy test within 7 days of randomization to Metformin. Subjects are
             considered not of child-bearing potential if they are surgically sterile or they are
             postmenopausal for greater than 12 months.

        Exclusion Criteria:

          -  Poorly differentiated cancer or any of the high-risk subtypes of endometrial cancer
             including serous, clear cell, or carcinosarcoma

          -  History of diabetes mellitus Type 1 or Type 2.

          -  Receiving metformin prior to enrollment

          -  Known hypersensitivity to metformin.

          -  Unable to swallow and retain oral medication.

          -  Pregnant or lactating.

          -  Previous or concurrent malignancies, except non-melanoma skin cancers, unless
             curatively treated and with no evidence of recurrence for &gt; 5 years

          -  If the physician feels that the candidate is not suitable for the study, he/she will
             be excluded.

          -  Currently taking biguanides, sulfonylurea drugs, thiazolidinediones, insulin, or mTOR
             or DPP-4 inhibitors or having taken any of these medications during the 12 weeks
             prior to study participation.

          -  Clinical symptoms of gastrointestinal obstruction or bleeding and consideration for
             immediate surgery or immediate neoadjuvant chemoradiation.

          -  History of lactic or other metabolic acidosis.

          -  Uncontrolled infectious disease.

          -  History of positivity for human immunodeficiency virus (HIV).

          -  History of congestive heart failure requiring pharmacologic treatment.

          -  History of excessive alcohol abuse, defined by a habitual intake of more than three
             drinks daily.

          -  Mal-absorption syndrome, disease affecting gastrointestinal function, or previous
             resection of the stomach or small bowel.

          -  Current use of medications for weight loss.

          -  Currently taking cimetidine, thiazide diuretics or cephalexin. If a patient needs
             some of these agents, alternative agents should be substituted.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander Burnett, MD</last_name>
    <phone>501-296-1099</phone>
    <email>ABurnett@uams.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandy Annis</last_name>
    <phone>501-686-8274</phone>
    <email>amannis@uams.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Burnett, MD</last_name>
      <phone>501-296-1099</phone>
      <email>ABurnett@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandy Annis</last_name>
      <phone>501-686-8274</phone>
      <email>amannis@uams.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Burnett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 26, 2016</lastchanged_date>
  <firstreceived_date>June 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
